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Background
Recombinant Adenovirus serotype 5 (Ad5) vectors have
been used as vaccine platforms to induce cell mediated
and humoral immune responses in human clinical stud-
ies. The immune response induced by Ad5 vaccines can be
mitigated due to pre-existing Ad5 immunity. The Ad5 [E1-
, E2b-] platform is an Ad5 vector with novel deletions in
the Ad5 DNA polymerase and the preterminal protein
genes contained in the E2b region. This vector has been
reported to allow for induction of potent immune
responses to transgene antigens in the presence of Ad5
immunity. This vector expressing a tumor associated anti-
gen is now advancing to clinical evaluation as a cancer
therapeutic agent. We previously reported the use of the
Ad5 [E1-, E2b-] platform to induce cellular immune
responses (CMI) against HIV-1 Gag in Ad5 hyper immune
mice.
Methods
Here, the effectiveness of this vaccine platform was evalu-
ated using a triad mixture of HIV-1 Gag, Pol, and Nef as
antigenic transgenes.
Results
Broad CMI was induced following vaccination with the
HIV-1 expressing vectors in Ad5 naive and Ad5 immu-
nized mice. A mixture of the three vaccines induced CMI
against each transgene product even in the presence of
hyper Ad5 immunity. These studies revealed that CMI
responses to immunization with Ad5 [E1-, E2b-]-gag, Ad5
[E1-, E2b-]-pol or Ad5 [E1-, E2b-]-nef vectors were trans-
gene specific and did not induce CMI responses against
irrelevant antigens such as carcinoembryonic antigen
(CEA), herpes simplex virus glycoprotein B (HSV),
cytomegalovirus (CMV) or influenza virus antigens.
Conclusion
We are evaluating this recombinant triad viral vector as an
HIV-1 vaccine in a non-human primate model.
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